SANTA ROSA, CA - July 26, 2011
Osseon® Therapeutics, Inc. announced today that the first “Osseoplasty™” cases were performed in India this month at the Command Hospital in Chandigarh by Dr. Col M. Sreenivas and in New Delhi at the All India Institute of Medical Sciences (AIIMS) by Prof. Arvind Jaysawal. Two additional cases were performed at the prestigious, private Max Super Specialty Hospital in New Delhi by Drs. Sandeep Vaishya and Bipin Walia. No complications resulted in any of the patients treated. All patients presented with symptomatic compression fractures, and experienced prompt, meaningful symptomatic improvement. Prof. Arvind Jaysawal from AIIMS and the other participating leading neurosurgeons viewed a demonstration of Osseoplasty and expressed interest in using the system over other systems currently in the marketplace.
Initial data on the first 1000 Osseoplasty cases were also presented to over 50 spine surgeons by Prof. Anand Agarwal, to the New Delhi Spine Society Meeting on July 23, 2011, and to over 200 orthopedic surgeons at the Delhi Medicon Orthopedic Surgeon’s Meeting on July 24, 2011, enabling a multitude of experienced spine surgeons throughout India to see the advantages of the Osseoplasty system. Many of these surgeons expressed their interest in applying Osseoplasty in their daily practice.
Osseon anticipates rapid adoption of its medical devices for percutaneous vertebral augmentation in multiple centers throughout the Indian subcontinent over the next six months. Other centers in Southern Asia should follow within the next twelve months, as more surgeons gain experience and exposure to Osseon’s products, and the advantages of its steerable, unipedicular system of vertebral body access and cement delivery.
“This is an exciting step forward for Osseon as a company, and for the treatment of spinal fractures in one of the most populous countries in the world. We look forward to enhancing our relationship with clinicians throughout India as word of our system spreads through the spine community in Southern Asia", noted John Stalcup Ph.D., CEO of Osseon, who attended the cases at the Command Hospital in Chandigarh and AIIMS in New Delhi.
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Following the first clinical case performed in December 2008, over 2,000 Osseoplasty vertebral augmentation procedures have been performed in more than 40 states, Spain, Italy, the UK, South Africa and most recently India.
Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union. For more information, visit our website at www.osseon.com.
Osseon® is a registered trademark of Osseon Therapeutics, Inc. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.
For more information, please contact Osseon Therapeutics, Inc.
Michael Bivens, Director of Business Development, Osseon Therapeutics, 707.636.5953